Boronic Acid Derivatives for β-Lactamase Blocking in Resistant Strains
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The rapid emergence of antibiotic-resistant bacteria, particularly those expressing β-lactamases such as Acinetobacter baumannii, has limited the effectiveness of β-lactam antibiotics, necessitating the development of improved β-lactamase inhibitors.
Innovation Solution
Development of boronic acid derivatives with specific structural formulas (I, II, III, and IV) that act as potent β-lactamase inhibitors, capable of inhibiting various classes of β-lactamases, including class A, B, and D, thereby restoring the efficacy of β-lactam antibiotics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If β-lactam antibiotics are used to treat bacterial infections, then effective treatment is achieved against susceptible bacteria, but treatment fails against β-lactamase-producing resistant strains
Solution Approach 1:
The patent introduces boronic acid derivatives as intermediary compounds that specifically bind to and inhibit β-lactamase enzymes. These inhibitors act as mediators between the antibiotic and the resistant bacteria, preventing the enzyme from degrading the antibiotic while allowing the antibiotic to maintain its therapeutic function against susceptible bacteria.
Solution Approach 2:
The boronic acid inhibitors are designed to preemptively block the β-lactamase enzyme's active site before the enzyme can degrade the β-lactam antibiotic. By applying this preliminary anti-action, the patent prevents the harmful degradation process from occurring, thereby preserving antibiotic effectiveness against resistant strains.
2Adaptability or versatility
If broad-spectrum β-lactam antibiotics are used to cover multiple bacterial strains, then treatment coverage is expanded, but selection pressure for resistance development increases
Solution Approach 1:
The patent converts the harmful effect of β-lactamase production into a beneficial target for inhibition. By designing boronic acid derivatives that specifically recognize and bind to the active site of β-lactamases, the invention transforms the resistance mechanism into a vulnerability that can be exploited therapeutically, allowing continued use of broad-spectrum antibiotics without selecting for resistance.
3Reliability
If carbapenem antibiotics are used to treat multidrug-resistant infections, then treatment options are maintained, but efficacy is lost against carbapenemase-producing strains
Solution Approach 1:
The patent employs boronic acid derivatives as intermediary inhibitors that specifically target carbapenemase enzymes. These compounds mediate protection by binding to the carbapenemase active site, preventing hydrolysis of carbapenem antibiotics and preserving their effectiveness against multidrug-resistant Gram-negative bacteria.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The boronic acid derivatives effectively inhibit β-lactamases, enhancing the effectiveness of β-lactam antibiotics against resistant bacterial strains, providing a therapeutic option for infections caused by multi-drug-resistant bacteria.
Implementation Method 1
boronic acid derivatives with specific structural formulas (I, II, III, and IV) that act as potent β-lactamase inhibitors, capable of inhibiting various classes of β-lactamases
Data Source
AI summary
Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the method of use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents, for example, β-lactamase inhibitors (BLIs).